This FDA report on Dabur India’s facility in Dadra and Nagar Haveli is honestly not small thing ah . When inspection starts talking about manufacturing lapses,maintenance issues and data integrity problems,consumer trust takes direct hit.
And timing also makes it more uncomfortable,because Indian pharmaceutical companies are already under tighter watch from US regulators . So any finding like this does not stay as internal factory matter only,it becomes reputation issue also.
According to US Food and Drug Administration (FDA),inspection found multiple deficiencies at Dabur India’s manufacturing facility . Main concerns were around equipment cleaning,maintenance,quality control procedures and records which allegedly did not reflect real picture properly .
Few points standing out from report:
- Inspectors reported potential microbiological contamination risks at plant .
- Some manufacturing records were allegedly altered to misrepresent product safety.
- Dabur's management failed to review production records adequately.
But tbh,the most disturbing part is what inspectors reportedly saw inside raw material warehouse . live bird and droppings were found there . In any healthcare product manufacturing setup,this kind of thing sounds completely unacceptable.
And then there is another visual from report which is also worrying . Large portions of ceiling surfaces in storage areas were covered with unidentified black substance . Nobody wants to hear this connected with products meant for health and daily use.
FDA report also questioned reliability of microbiological testing at plant . Inspectors reportedly found contamination in several samples during visit,and that raises basic doubt about how quality checks were being handled before inspection.
Dabur India,which supplies Ayurvedic and over-the-counter healthcare products,has not yet responded to requests for comments regarding FDA findings . Companies receiving FDA Form 483 usually have to submit corrective action plans for deficiencies .
And now big question is what happens next for Dabur in US market . Because once trust issue starts around safety,records and cleanliness,it does not disappear easily…
